The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: A new paradigm supported by more evidence

European Heart Journal

Volumn 36, Issue 31, 2015, Pages 2110-2118

  Robinson, Jennifer G ^a   Stone, Neil J ^b  

^a UNIVERSITY OF IOWA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cardiovascular risk; Cholesterol; Guideline; Primary prevention; Risk assessment; Secondary prevention

Indexed keywords

CARDIOVASCULAR AGENT; CHOLESTEROL; EZETIMIBE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); NATIONAL HEALTH ORGANIZATION; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE;

EID: 84937529439     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv182     Document Type: Article

References (36)

1. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PWF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25, Part B): 2889-2934.
2. American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care, 2015;38(Suppl. 1):S49-S57.
3. National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (clinical guideline 181). 2014 www.nice. org.uk/guidance/CG181 (24 July 2014).
4. Scott R. Implementing the new ACC/AHA cholesterol and CV risk reduction guidelines in a large health system. 2014 http://cardiometabolic.cardiosource.org/Hot-Topics/2014/11/Implementing-New-ACC-AHA-Cholesterol-and-CV-Risk-Reduction-Guidelines.aspx (November 2014).
5. Crawford C. AAFP endorses ACC/AHA cholesterol management guidelines with qualifications. 2014 http://www.aafp.org/news/health-of-the-public/20140618 cholesterolgdlnendorse.html (June 2014).
6. Ray KK, Kastelein JJP, Matthijs Boekholdt S, Nicholls SJ, Khaw K-T, Ballantyne CM, Catapano AL, Reiner Z, Luscher TF. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014;35:960-968.
7. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV. National lipid association recommendations for patient-centered management of dyslipidemia: part 1-full report. J Clin Lipidol 2015;9:129-169.
8. Grundy SM. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. J Clin Lipidol 2013;7: 561-565.
9. Cook NR, Ridker P. Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the women's health study. JAMA Intern Med 2014;174:1964-1971.
10. Cannon C, On behalf of the IMPROVE-IT Study Group. IMPROVE-IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndrome. In: Presented at the American Heart Association Scientific Sessions, November 17, 2014. Circulation 2014;130: 2105-2126.
11. The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropriprant in high-risk patients. N Engl J Med 2014;371:203-2012.
12. Institute of Medicine. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press; 2011.
13. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee IM, Lichtenstein AH, Loria CM, Millen BE, Nonas CA, Sacks FM, Smith Jr SC, Svetkey LP,Wadden TA, Yanovski SZ. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25, Part B):2960-2984.
14. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014;63(25, Part B):2985-3023.
15. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PWF. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25, Part B):2935-2959.
16. Stone N, Robinson J, Lichtenstein A, Bairey Merz C, Blum C, Eckel R, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, Wilson PWF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation 2014;129(Suppl. 2):S1-S45.
17. Pencina MJ, Navar-Boggan AM, D'Agostino RB, Williams K, Neely B, Sniderman AD, Peterson ED. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014;370:1422-1431.
18. Paixao ARM, Ayers CR, Berry JD, de Lemos JA, Khera A. Atherosclerotic cardiovascular disease prevention: a comparison between the third adult treatment panel and the new 2013 treatment of blood cholesterol guidelines. Circ Qual Cardiovasc Outcomes 2014;7:778-779.
19. Johnson KM, Dowe DA. Accuracy of statin assignment using the 2013 AHA/ACC cholesterol guideline versus the 2001 NCEP ATP III guideline: correlation with atherosclerotic plaque imaging. J Am Coll Cardiol 2014;64:910-919.
20. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Calhoun HM, Gotto AM Jr, Ridker PM, Grundy SM, Kastelein JJP. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 2014;64:485-494.
21. Puri R, Nissen SE, Shao M, Uno K, Kataoka Y, Kapadia SR, Tuzcu EM, Nicholls SJ. Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy. Am J Cardiol 2014;114: 1465-1472.
22. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574.
23. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267.
24. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
25. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, Gotto AM, Greten H, Kastelein JJP, Shepherd J, Wenger NK; the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435.
26. Karmali KN, Goff DC Jr, Ning H, Lloyd-Jones DM. A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol 2014;64:959-968.
27. Muntner P, Colantonio LD, Cushman M, Goff DC Jr, Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd-Jones DM, Safford MM. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA 2014;311:1406-1415.
28. DeFilippis AP, Young R, Carrubba CJ, McEvoy JW, Budoff MJ, Blumenthal RS, Kronmal RA, McClelland RL, Nasir K, Blaha MJ. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohortcalibration and discrimination among CVD risk scores. Ann Intern Med 2015;162:266-275.
29. Kavousi M, Leening MG, Nanchen D, Greenland P, Graham IM, Steyerberg EW, Ikram MA, Stricker BH, Hofman A, Franco OH. Comparison of application of the ACC/AHA guidelines, adult treatment panel III guidelines, and European society of cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014;311:1416-1423.
30. Perk J, De Backer G, Gohlke H, Graham I, ReinerZ , Verschuren WMM, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte OP Reimer WJM, Vrints C, Wood D, Zamorano JL, Zannad F. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 2012;223:1-68.
31. Randomized Trial to Prevent Vascular Events in HIV-REPRIEVE, ClinicalTrials.gov identifier NCT02344290 Jan 15, 2015https://clinicaltrials.gov/ct2/show/NCT02344290term=HIV+AND+statin&rank=19 (22 January 2015).
32. Willeit P, Kiechl S, Kronenberg F, Witztum JL, Santer P, Mayr M, Xu Q, Mayr A, Willeit J, Tsimikas S. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck study. J Am Coll Cardiol 2014;64:851-860.
33. Karalis I, Rensen PCN, Jukema JW. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside. Circ Cardiovasc Qual Outcomes 2013;6: 360-366.
34. Urban D, Pöss J, Böhm M, Laufs U. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol 2013;62:1401-1408.
35. Robinson J, FarnierM, KrempfM, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pardy R, Chaudhari U, Kastelein JJP. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489-1499.
36. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-1509.